The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
New Antiepileptic Drugs: Comparison of Key Clinical Trials
Abstract
Summary: Purpose: Data accrued from clinical trials of five new antiepileptic drugs (AEDs) are compared for efficacy in reducing seizures and self‐reported adverse events as a basis of selection among new AEDs. Drawbacks to use of these data also are demonstrated. Methods: A review of double‐blind, placebo‐controlled clinical trials of a new AED or placebo added to a standard AED provided data on reduction of complex partial seizures (CPSs). Success is 50% fewer CPSs with a new AED or placebo; Overall Improvement is the success rate with drug minus the success rate with placebo. Adverse events were tabulated from product‐labeling lists of COSTART items (incidence, 5%). The Summary Complaint score is the total number of reports of individual events for each AED. Results: Efficacy data demonstrate differences in Overall Improvement rates among five new AEDs and placebos (p =0.001). However, rates of response to placebo also differed significantly among trials (p = 0.01). Adverse events predominantly affect central nervous system, psychiatric, and general body systems. However, patients in the placebo control groups did not consistently report adverse effects. Summary Complaint scores differ among the five new AEDs, but variability in use of COSTART terms nullifies comparisons. Conclusions: Comparisons of data for five new AEDs provide information for selection among treatments when a second drug is needed to improve control of CPSs. However, significant differences among the control groups and other problems make comparisons between trials problematic. The final choice should be based on the need of the individual patient for superior seizure control versus minimal adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Cited by
Book Review: GABA and Glutamate in the Human Brain
Petroff, O. A. C. (2002) · The Neuroscientist · doi:10.1177/1073858402238515 · Cited by 675
Ben‐Menachem, E., & Falter, U. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb04605.x · Cited by 409
Self-citationVagus nerve stimulation, side effects, and long-term safety
Ben-Menachem, E. (2001) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-200109000-00005 · Cited by 400
Self-citationEngel, J., Wiebe, S., French, J., Sperling, M., Williamson, P., Spencer, D., Gumnit, R., Zahn, C., Westbrook, E., & Enos, B. (2003) · Epilepsia · doi:10.1046/j.1528-1157.2003.48202.x · Cited by 400
Self-citationIntractable epilepsy: management and therapeutic alternatives
Schuele, S. U., & Lüders, H. O. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70108-x · Cited by 344
Metadata
- Authors
- Cramer, J. A., Fisher, R., Ben‐Menachem, E., French, J., & Mattson, R. H.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 1999-05
- Volume
- 40
- Issue
- 5
- Pages
- 590-600
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2073587246
- Cited by
- 187
- References
- 1
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New Antiepileptic Drugs: Comparison of Key Clinical Trials. https://app.cochat.ai/papers/10.1111/j.1528-1157.1999.tb05561.x
- The paper
- Cramer, J. A., Fisher, R., Ben‐Menachem, E., French, J., & Mattson, R. H. (1999). New Antiepileptic Drugs: Comparison of Key Clinical Trials. Epilepsia. https://doi.org/10.1111/j.1528-1157.1999.tb05561.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.